Conference "Innovations in medical technology", organized by the Foundation and the Skolkovo Open University Skolkovo with the support of a specialized department of the publishing house Elsevier, illuminating the development of the medical industry in the press, and the New York-based group of investors Life Sciences Angel Network (LSAN) was held in Moscow on April 2-3.
To date, the biomedical cluster, Skolkovo registered more than 140 different startups in the field of systems biology, bioinformatics, biotechnology, and in various fields of medicine. What are they — Skolkovo projects? The event was organized by the "Parade of start-ups," in which to participate were selected 10 initiatives Russian scientists who have applied for financial aid in the Skolkovo Foundation. It should be said that the "startup" — a word that is becoming increasingly familiar to our ear and slowly taking root in the Russian language. (In English «start up» has several meanings — jump, jump, occur; (unexpectedly) to appear, grow rapidly. Here, the mean high-technology startup project that can be implemented quickly and create the enterprise production or a specific product, which would be generate income and return on investment.) Demonstrated work was diverse and represented different stages of "occurrence" in the Skolkovo project. The task of the organizers, obviously, was to show the participants of the conference startups biomedical cluster in all their diversity. Some of them are focused on developing new drugs. So, Sergey Nikolenko of the company Synthegenics Pharmaceuticals spoke about the results of 11 years of research conducted in collaboration with foreign scientists, resulting in cytotoxic drug was obtained bacterial origin, which proved quite effective in the fight against colorectal cancer. To launch the drug on the market is required, according to the head of this project, one year and about 10 million rubles.
Two reports were made by the head company MBF-8 and MBF-12 Roziev Rahim had submitted two "therapeutic molecules". One of them is a high adjuvant chemotherapy, i.e. protecting stem cells in bone and promotes suppression of irradiation process of metastasis of the cancer. As explained Roziev Rahim, this substance is used Badakh, particularly in the treatment of infertility. It is assumed that the farmsubstanitsiya should be on the market within 2 years. Another "molecule" — should help in Alzheimer’s disease, but the development is still at an early stage, and for the implementation of the project will take more time.
In the development of new drugs there is a pressing question as to which biological models to test them. Frequently used for these purposes in laboratory animals or their culture cells. Head of Laboratory of the genetic basis of cellular technology Institute of General Genetics. NI Vavilov, RAS, etc. b. n. Sergey Kiselev proposed the creation of a specialized bank of human cells for testing of drug substances. According to him, every year more than 8 billion dollars spent on the development of medicines are wasted, as is often the last stages it appears that pharmaceutical substances ineffective. If you test it targeted, for example, on certain tumor cells or bearing the mutation, which is a feature of certain genetic variations and disease, then see if there is the prospect of whether further study of the activity of "molecule candidate" can be in the initial stages of the study, so saving way of time, effort and money. The project, according to Sergei Kiselyov, can be implemented by 2015.
The current project (in light of the increasing worldwide incidence of cardiovascular disease) was presented by the Deputy Director of the Institute of Cardiology (Tomsk), Doctor of. Shamil Akhmedov. In cooperation with Tomsk chemists, surgeons are looking for ways to combat atherosclerosis. We have tested a lot of nanoparticles synthesized in the laboratory, until, finally, some of them have not been able to penetrate into the fatty atherosclerotic plaque and to influence its structure. According Shamilja Ahmedov the nanoparticles (based on iron oxide and carbon) "in vitro" show the ability to reduce the level of triglycerides and "bad" LDL cholesterol levels. Scientists plan to study further the mechanism of action of nanoparticles. The most real to them is the prospect of using these particles to coat stents — implants used to "fix" the damaged blood vessel atherosclerotic process.
Two projects focused equipment. In one of them represented the modulation interference microscope (MIM) with high spatial resolution characteristics and performance to investigate the properties of materials. Developer — Amfora Labs, presented a novelty Alex Loparev. Another development — a biomechanical stimulator simulator to repair damaged muscles, created by BIOM-Volna. Project manager Gasparov Markar said that Samara scientists have created a prototype that is being tested at the Department of Rehabilitation Medicine Samara Medical University. The plant can be used not only for bio-stimulation of neuromuscular tissue, but also for the vacuum, anti-cellulite massage. In the two years during which the prototype was created, was spent about 35 thousand dollars. Scientists believe that in order to bring development to the pre-production stage will require about 170 thousand dollars, with nothing and asked for help in the Skolkovo Foundation.
The parade was attended by three startups in the "Information technologies in medicine." The head of one of them, iCare, Sergei Grizzly, offered a computer device (bracelet) for single seniors, allowing relatives remotely monitor their condition, Elena Dmitrieva, representing the company Text4Baby, offered SMS-service to monitor the involvement of young people in anti-social processes, graduates Faculty of Bioengineering and Bioinformatics, Moscow State University. MV University, created under the leadership of a company FutureMother Vita Stepanova, propose to merge the social network of pregnant women. According to the Vita Stepanova, if pregnant women sick of pickles, they could discuss these issues, using the services of a specialized social networks. Because, as calculated by the authors of the project market of goods and services for pregnant women in Russia is about $ 3.2 billion, this social network could become quite profitable.
Microscope MIM 320 firms «Amfora Labs»
Processing of the image obtained by the MIM 320
One of the developments of the company, "Biome-Wave" to restore muscle damage
Author: Larissa Aksenov